RELATED NEWS
Life Sciences PE: The Misunderstood Opportunity
Christoph Broja, Partner at EQT, dismantled the myth that biotech is too risky for private...
Secondaries in 2026: The Active Allocator's Edge
Iyobosa Adeghe from Coller Capital, made the case for why sophisticated investors are increasingly...
CVC DIF Shifts from Refinancing to Revenue Optimisation as High Rates Transform Infrastructure Value Creation
CVC DIF shifts focus from refinancing to revenue optimisation in response to high interest rates,...
.png)